Online inquiry

IVTScrip™ mRNA-Anti-RABVgp4, CR4098(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6204MR)

This product GTTS-WQ6204MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets RABVgp4 gene. The antibody can be applied in Rabies research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NP_056796.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1489856
UniProt ID P08667
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-RABVgp4, CR4098(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6204MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9585MR IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA JNJ-61186372
GTTS-WQ7245MR IVTScrip™ mRNA-Anti-STAB1, FP-1302(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA FP-1302
GTTS-WQ7338MR IVTScrip™ mRNA-Anti-VTCN1, FPA-150(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA FPA-150
GTTS-WQ13632MR IVTScrip™ mRNA-Anti-TNFSF4, R4930(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA R4930
GTTS-WQ9668MR IVTScrip™ mRNA-Anti-CD19&CD3E, JNJ-64052781(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA JNJ-64052781
GTTS-WQ7560MR IVTScrip™ mRNA-Anti-GPC3, GC33(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA GC33
GTTS-WQ7861MR IVTScrip™ mRNA-Anti-APCS, GSK-2398852(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA GSK-2398852
GTTS-WQ3048MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA Anti-PTK7 ADC
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW